OTCMKTS:RGRX

RegeneRx Biopharmaceuticals - RGRX Stock Forecast, Price & News

$0.12

0.00 (0.00%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.12
▼
$0.12
50-Day Range: $0.11
▼
$0.15
52-Week Range: $0.10
▼
$0.25

Volume: 200 shs
Average Volume: 9,083 shs
Market Capitalization: $17.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Stock

RegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RGRX Stock News Headlines

March 1, 2023 | marketwatch.com

2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029

February 25, 2023 | marketwatch.com

Biopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028

March 26, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

February 24, 2023 | marketwatch.com

Biopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027

February 12, 2023 | finance.yahoo.com

Biopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

January 31, 2023 | finance.yahoo.com

Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

January 27, 2023 | markets.businessinsider.com

$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying

January 18, 2023 | marketwatch.com

Biopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]

March 26, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

January 17, 2023 | marketwatch.com

Biopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the Report

January 3, 2023 | finance.yahoo.com

Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

November 18, 2022 | finance.yahoo.com

Biopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic Partnerships

October 24, 2022 | finance.yahoo.com

RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease

September 30, 2022 | investing.com

Clover Biopharmaceuticals Ltd (2197)

September 27, 2022 | finance.yahoo.com

RegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)

August 22, 2022 | finance.yahoo.com

RegeneRx Issues 2022 Letter To Stockholders

July 18, 2022 | finance.yahoo.com

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

June 22, 2022 | finance.yahoo.com

RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

May 4, 2022 | finance.yahoo.com

Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

February 11, 2022 | finance.yahoo.com

RegeneRx Consultant to Receive Prestigious Award for Contributions in Field of Health

February 7, 2022 | nasdaq.com

RGRX Real-Time Quotes

January 25, 2022 | finance.yahoo.com

Researchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol Injury

January 20, 2022 | nasdaq.com

RGRX After-Hours Quotes

January 12, 2022 | seekingalpha.com

Microcap RegeneRx surges 17% on regulatory development for ophthalmic candidate

December 17, 2021 | finance.yahoo.com

RegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022

November 29, 2021 | finance.yahoo.com

RegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye Syndrome

October 29, 2021 | finance.yahoo.com

Clinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association Meeting

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RGRX Company Calendar

Today: 3/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:RGRX
Previous Symbol: OTC:RGRX
CUSIP: N/A
CIK: 707511
Web: www.regenerx.com
Phone: (301) 208-9191
Fax: 301-280-1996
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,600,000.00
Net Margins: -2,326.70%
Pretax Margin: -2,326.70%
Return on Equity: N/A
Return on Assets: -200.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.05
Quick Ratio: 1.05

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 214.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.02) per share
Price / Book: -5.98

Miscellaneous

Outstanding Shares: 143,550,000
Free Float: 125,606,000
Market Cap: $17.17 million
Optionable: Not Optionable
Beta: 0.56

Key Executives

Allan L. Goldstein
Chairman & Chief Scientific Officer

J. J. Finkelstein
President, Chief Executive Officer & Director

Key Competitors

View All Competitors

RGRX Stock - Frequently Asked Questions

How have RGRX shares performed in 2023?: RegeneRx Biopharmaceuticals' stock was trading at $0.1389 at the beginning of 2023. Since then, RGRX stock has decreased by 13.9% and is now trading at $0.1196.
View the best growth stocks for 2023 here.
What other stocks do shareholders of RegeneRx Biopharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), Inpixon (INPX), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA).
What is RegeneRx Biopharmaceuticals' stock symbol?: RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

How do I buy shares of RegeneRx Biopharmaceuticals?: Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RegeneRx Biopharmaceuticals' stock price today?: One share of RGRX stock can currently be purchased for approximately $0.12.
How much money does RegeneRx Biopharmaceuticals make?: RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) has a market capitalization of $17.17 million and generates $80,000.00 in revenue each year.
How can I contact RegeneRx Biopharmaceuticals?: RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The official website for the company is www.regenerx.com. The biopharmaceutical company can be reached via phone at (301) 208-9191, via email at info@regenerx.com, or via fax at 301-280-1996.

This page (OTCMKTS:RGRX) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial